FHTX Foghorn Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FHTX

Price (delayed)

$5.99

Market cap

$254.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.34

Enterprise value

$218M

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The ...

Highlights
FHTX's gross profit has surged by 78% year-on-year and by 4.9% since the previous quarter
The company's revenue has surged by 78% YoY and by 4.9% QoQ
FHTX's quick ratio is down by 36% year-on-year and by 20% since the previous quarter
The equity has contracted by 35% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://foghorntx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of FHTX
Market
Shares outstanding
42.57M
Market cap
$254.97M
Enterprise value
$218M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.38
Earnings
Revenue
$34.16M
EBIT
-$94.2M
EBITDA
-$85.54M
Free cash flow
-$119.33M
Per share
EPS
-$2.34
Free cash flow per share
-$2.84
Book value per share
-$1.83
Revenue per share
$0.81
TBVPS
$6.81
Balance sheet
Total assets
$285.92M
Total liabilities
$363.11M
Debt
$45.07M
Equity
-$77.19M
Working capital
$181.75M
Liquidity
Debt to equity
-0.58
Current ratio
4.11
Quick ratio
4.03
Net debt/EBITDA
0.43
Margins
EBITDA margin
-250.4%
Gross margin
100%
Net margin
-288.2%
Operating margin
-315.9%
Efficiency
Return on assets
-30%
Return on equity
N/A
Return on invested capital
-37.2%
Return on capital employed
-41.4%
Return on sales
-275.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FHTX stock price

How has the Foghorn Therapeutics stock price performed over time
Intraday
-1.96%
1 week
9.11%
1 month
-16.92%
1 year
-5.97%
YTD
-7.13%
QTD
-10.73%

Financial performance

How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$34.16M
Gross profit
$34.16M
Operating income
-$107.91M
Net income
-$98.43M
Gross margin
100%
Net margin
-288.2%
FHTX's gross profit has surged by 78% year-on-year and by 4.9% since the previous quarter
The company's revenue has surged by 78% YoY and by 4.9% QoQ
The company's net margin rose by 49% YoY and by 9% QoQ
FHTX's operating margin is up by 48% YoY and by 10% QoQ

Growth

What is Foghorn Therapeutics's growth rate over time

Valuation

What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
7.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.38
Foghorn Therapeutics's EPS has increased by 11% YoY and by 4.9% from the previous quarter
The equity has contracted by 35% from the previous quarter
The company's revenue has surged by 78% YoY and by 4.9% QoQ
FHTX's P/S is 27% lower than its last 4 quarters average of 10.1

Efficiency

How efficient is Foghorn Therapeutics business performance
Foghorn Therapeutics's ROS has soared by 51% YoY and by 11% from the previous quarter
The ROA has contracted by 23% YoY and by 3.8% from the previous quarter
FHTX's return on invested capital is down by 17% year-on-year and by 8% since the previous quarter

Dividends

What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FHTX.

Financial health

How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 21% lower than its total liabilities
FHTX's quick ratio is down by 36% year-on-year and by 20% since the previous quarter
The current ratio has contracted by 35% YoY and by 19% from the previous quarter
The company's debt is 158% higher than its equity
The debt to equity has shrunk by 100% YoY but it is up by 29% QoQ
The equity has contracted by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.